When was Synaffix founded?

Synaffix was founded in 2010 and raised its 1st funding round 4 years after it was founded.

Where is Synaffix located?

Synaffix is headquartered in Nijmegen, Netherlands.

How many employees does Synaffix have?

As of Mar 31, 2026, the latest employee count at Synaffix is 61.

Is Synaffix a funded company?

Synaffix is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 18, 2014.

When was the latest funding round of Synaffix?

Synaffix's latest funding was a $***** Series A round on Feb 18, 2014, with participation from 4 investors.

Where does Synaffix rank among its competitors?

Synaffix ranks 563rd amongst 3334 active competitors, of which 1123 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Synaffix?

Synaffix's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Synaffix - 2026 Company Profile, Team, Funding & Competitors

Q: Is Synaffix an acquired company?

Synaffix got acquired by Lonza on Jun 01, 2023.

Synaffix is an acquired company based in Nijmegen (Netherlands), founded in 2010. It operates as an Antibody drug conjugate technology platform. Synaffix has raised an undisclosed amount in funding. The company has 3334 active competitors, including 1123 funded and 784 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Synaffix is developing antibody-drug conjugate (ADC) technology platform. Its ADC technology, GlycoConnect, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with their payload-enhancing linker technology, HydraSpace, and BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability. The company is planning to initiate clinical trials for various cancers.

Website: synaffix.com
Social
Email ID: *****@synaffix.com

Key Metrics

Founded Year

2010

Location

Nijmegen, Netherlands

Stage

Acquired

Latest Funding Round

Series A, Feb 18, 2014, $*****

Investors

Aravis & 4 more

Ranked

563^rd among 3334 active competitors

Employee Count

61 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3091 more

Exit Details

Acquired by Lonza (Jun 01, 2023)

View Synaffix's full profile

Synaffix got acquired by Lonza on Jun 01, 2023 at an acquisition amount of $*****.

Click here to take a look at Synaffix's acquisition in detail

Synaffix has raised funding over 1 round. Its latest funding round was a Series A round on Feb 18, 2014 for $*****. 4 investors participated in its latest round. Synaffix has 5 institutional investors.

Here is the list of recent funding rounds of Synaffix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 18, 2014	7209498	Series A	1171627	9241590	5222049	8119487

Access funding benchmarks and valuations. Sign up today!

View details of Synaffix's funding rounds and investors

Synaffix's employee count trend

Synaffix has 61 employees as of Mar 26. Here is Synaffix's employee count trend over the years:

Uncover Synaffix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Synaffix include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Synaffix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
563rd	Synaffix 2010, Nijmegen (Netherlands), Acquired	Antibody drug conjugate technology platform	-	Aravis, Aravis & 3 others	51/100